LAVA Therapeutics’ $83 Million Series C Financing

Osborne Clarke advised LAVA Therapeutics on the deal. LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

This content is for Standard 1 Year members only.
Login Join Now